Basilea Pharmaceutica AG (SWX:BSLN)
53.80
-0.60 (-1.10%)
Feb 20, 2026, 5:31 PM CET
Basilea Pharmaceutica AG Revenue
In the year 2025, Basilea Pharmaceutica AG had annual revenue of 232.38M CHF with 11.43% growth. Basilea Pharmaceutica AG had revenue of 128.42M in the half year ending December 31, 2025, with 76.57% growth.
Revenue
232.38M
Revenue Growth
+11.43%
P/S Ratio
2.88
Revenue / Employee
1.29M
Employees
180
Market Cap
668.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 232.38M | 23.84M | 11.43% |
| Dec 31, 2024 | 208.54M | 50.91M | 32.30% |
| Dec 31, 2023 | 157.63M | 9.87M | 6.68% |
| Dec 31, 2022 | 147.77M | -357.00K | -0.24% |
| Dec 31, 2021 | 148.12M | 20.49M | 16.06% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Idorsia | 232.51M |
| Newron Pharmaceuticals | 55.93M |
| Santhera Pharmaceuticals Holding AG | 49.02M |
| BioVersys AG | 1.31M |
| Xlife Sciences AG | 839.38K |
| Molecular Partners AG | 681.00K |
| Addex Therapeutics | 158.54K |
Basilea Pharmaceutica AG News
- 2 days ago - Basilea Pharmaceutica Ltd (BPMUF) Full Year 2025 Earnings Call Highlights: Strong Revenue ... - GuruFocus
- 2 days ago - Full Year 2025 Basilea Pharmaceutica AG Allschwil Earnings Call Transcript - GuruFocus
- 2 days ago - Basilea Pharmaceutica AG (BPMUF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Basilea Pharmaceutica AG 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 3 days ago - Basilea Pharmaceutica AG GAAP EPS of CHF 3.14, revenue of CHF 232.4M - Seeking Alpha
- 3 days ago - Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance - GlobeNewsWire
- 11 days ago - Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea - GlobeNewsWire
- 5 weeks ago - Basilea Pharmaceutica Partners With INCATE To Advance Antibacterial And Antifungal Innovation - Nasdaq